Revive Sees Expanded Access Protocol Approved For Compassionate Use Of Bucillamine
Revive Therapeutics (CSE: RVV) this morning announced that it has received approval from the Independent Institutional Review Board (IRB) for
Read more
Revive Therapeutics
Revive Therapeutics To Conduct Phase 1 Clinical Trials For Psilocybin
Revive Therapeutics (CSE: RVV) is driving forward with its psilocybin studies. The company announced this morning that it has entered
Read more
Revive Receives Approval From Independent Review Board For Phase Three Study
Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials for the use of Bucillamine
Read more
Revive Submits for IRB Approval; Expects to Enroll Patients in September
This morning Revive Therapeutics (CSE: RVV, USA: RVVTF) announced they have submitted a clinical trial protocol to their independent Institutional
Read more
Revive Expands Phase 3 COVID-19 Study To Asia Pacific Region, Canada
Revive Therapeutics (CSE: RVV) announced this morning that it is expanding its phase 3 clinical trials following the approval granted
Read more
Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials
Revive Therapeutics (CSE: RVV) (OTC: RVVTF) is one step closer to conducting its phase 3 clinical trials for the use
Read more
Revive Therapeutics Receives First Prototype of Orally Dissolvable Psilocybin Film Strips
Revive Therapeutics (CSE: RVV) this morning announced that it has received the first set of orally dissolvable thin film strips,
Read more
Revive Announces Timeline For Phase 3 Studies, Sees Beneficial Psilocybin Developments
Revive Therapeutics (CSE: RVV) this morning announced that on the heels of receiving FDA approval for phase 3 clinical trials
Read more
Three Things to Know About ‘Phase 3 COVID Player’: Revive Therapeutics
Bucillamine Just Got Cleared for Phase 3 Trials of COVID-19 On Friday, July 31, 2020 Revive Therapeutics (CSE: RVV) (OTC:
Read more
Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment
It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this morning that the US Food
Read more